However, after 2 weeks, tumor volume assessment revealed most tumors from MRTX849 + anti–PD-1 group had relapsed in contrast to triple combination with anti–CTLA-4 where tumors kept regressing (Fig. 8C and fig. The gene discussed is CTLA4; the disease is neoplasm.